Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias

Summary: Bacground and objective: Pyrimidine 5’nucleotidase I and II activities of peripheral mononuclear cells were studied to evaluate their role in diagnosis, assessment of therapy and follow up of remission in acute leukaemias. Design and methods: Blood samples were obtained from 40 untreated pa...

Full description

Bibliographic Details
Main Authors: Haci Kemal Erdemli, Bahattin Adam, Nüket Bavbek
Format: Article
Language:English
Published: Karolinum Press 2004-01-01
Series:Acta Medica
Subjects:
Online Access:https://actamedica.lfhk.cuni.cz/47/2/0129/
_version_ 1818144672856408064
author Haci Kemal Erdemli
Bahattin Adam
Nüket Bavbek
author_facet Haci Kemal Erdemli
Bahattin Adam
Nüket Bavbek
author_sort Haci Kemal Erdemli
collection DOAJ
description Summary: Bacground and objective: Pyrimidine 5’nucleotidase I and II activities of peripheral mononuclear cells were studied to evaluate their role in diagnosis, assessment of therapy and follow up of remission in acute leukaemias. Design and methods: Blood samples were obtained from 40 untreated patients with acute lymphoblastic and myeloid leukaemia and 40 healthy controls, before the therapy and after remission. The correlation between the activity of the enzymes and the efficacy of therapy were established. The enzyme activities were measured by High-Performance Liquid Chromatography (HPLC), using the method described by Amici. For statistical analysis, Mann-Whitney U, Kruskal-Wallis and Wilcoxon methods were used. Results: Before the therapy, Pyrimidine 5’nucleotidase I levels in the leukaemic group were found to be significantly elevated when compared to the control group (p<0.001). Also Pyrimidine 5’nucleotidase II levels were significantly elevated before the therapy and during remission (p<0.02 and p<0.001 respectively). The isoenzyme activities were compared in patients who were in remission, who did not respond to therapy and in patients who died during the therapy, but no significant difference was found. Interpretation and conclusions: We concluded that, Pyrimidine 5’nucleotidase I and II activities can be used as markers for diagnosis and follow up of remission in patients with acute leukaemia. But, they can not have predictive value for prognosis.
first_indexed 2024-12-11T11:51:17Z
format Article
id doaj.art-b79e534079994859b70578d848564b39
institution Directory Open Access Journal
issn 1211-4286
1805-9694
language English
last_indexed 2024-12-11T11:51:17Z
publishDate 2004-01-01
publisher Karolinum Press
record_format Article
series Acta Medica
spelling doaj.art-b79e534079994859b70578d848564b392022-12-22T01:08:21ZengKarolinum PressActa Medica1211-42861805-96942004-01-0147212913110.14712/18059694.2018.78Pyrimidine 5’Nucleotidase I and II Activities in Acute LeukaemiasHaci Kemal Erdemli0Bahattin Adam1Nüket Bavbek2Fatih University, Faculty of Medicine, Department of Biochemistry and Clinical Biochemistry, Ankara, TurkeyFatih University, Faculty of Medicine, Department of Biochemistry and Clinical Biochemistry, Ankara, TurkeyFatih University, Faculty of Medicine, Department of Internal Medicine, Ankara, TurkeySummary: Bacground and objective: Pyrimidine 5’nucleotidase I and II activities of peripheral mononuclear cells were studied to evaluate their role in diagnosis, assessment of therapy and follow up of remission in acute leukaemias. Design and methods: Blood samples were obtained from 40 untreated patients with acute lymphoblastic and myeloid leukaemia and 40 healthy controls, before the therapy and after remission. The correlation between the activity of the enzymes and the efficacy of therapy were established. The enzyme activities were measured by High-Performance Liquid Chromatography (HPLC), using the method described by Amici. For statistical analysis, Mann-Whitney U, Kruskal-Wallis and Wilcoxon methods were used. Results: Before the therapy, Pyrimidine 5’nucleotidase I levels in the leukaemic group were found to be significantly elevated when compared to the control group (p<0.001). Also Pyrimidine 5’nucleotidase II levels were significantly elevated before the therapy and during remission (p<0.02 and p<0.001 respectively). The isoenzyme activities were compared in patients who were in remission, who did not respond to therapy and in patients who died during the therapy, but no significant difference was found. Interpretation and conclusions: We concluded that, Pyrimidine 5’nucleotidase I and II activities can be used as markers for diagnosis and follow up of remission in patients with acute leukaemia. But, they can not have predictive value for prognosis.https://actamedica.lfhk.cuni.cz/47/2/0129/Pyrimidine 5’nucleotidase isoenzymesLeukaemia
spellingShingle Haci Kemal Erdemli
Bahattin Adam
Nüket Bavbek
Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias
Acta Medica
Pyrimidine 5’nucleotidase isoenzymes
Leukaemia
title Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias
title_full Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias
title_fullStr Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias
title_full_unstemmed Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias
title_short Pyrimidine 5’Nucleotidase I and II Activities in Acute Leukaemias
title_sort pyrimidine 5 nucleotidase i and ii activities in acute leukaemias
topic Pyrimidine 5’nucleotidase isoenzymes
Leukaemia
url https://actamedica.lfhk.cuni.cz/47/2/0129/
work_keys_str_mv AT hacikemalerdemli pyrimidine5nucleotidaseiandiiactivitiesinacuteleukaemias
AT bahattinadam pyrimidine5nucleotidaseiandiiactivitiesinacuteleukaemias
AT nuketbavbek pyrimidine5nucleotidaseiandiiactivitiesinacuteleukaemias